Drugs / AZD8630
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07065331 | Jun → Sep 2025 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06795906 | Jan → Jun 2025 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06531811 | Aug → Oct 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05110976 | Dec 2021 → Aug 2023 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06529419 | Aug 2024 → Feb 2026 | asthma | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | AstraZeneca | Results AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio astrazeneca.com ↗
New Phase I safety and efficacy data for AZD8630/AMG 104, an inhaled TSLP inhibitor in patients with moderate-to-severe asthma. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06795906 ↗ |
| Route | Inhaled | “by dry powder inhaler (DPI) administration” NCT05110976 ↗ |